ArticleCureus2025
Protective Effects of Panax ginseng Extract on Endothelin-1- and Isoproterenol-Induced Cardiac Hypertrophy via Maintenance of Mitochondrial Function and Calcium-Reactive Oxygen Species (ROS) Homeostasis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitochondrial dysfunction and oxidative stress are central to the development of cardiac hypertrophy and heart failure. PURPOSE: To determine whether a standardized PG extract attenuates cardiac hypertrophy and whether its effects are associated with mitochondrial function and Ca
methodsNeonatal rat ventricular myocytes (NRVMs) were exposed to ET-1 to induce hypertrophy and mitochondrial fragmentation. Mitochondrial morphology, intracellular Ca²⁺, ROS, and adenosine triphosphate (ATP) levels were quantified by fluorescence imaging and biochemical assays. In mice, isoproterenol (ISO) was administered for 14 days to induce cardiac stress; PG was given orally. Cardiac structure and function were evaluated by histology and echocardiography. Expression of mitochondrial fusion/fission markers was analyzed. All experiments used predefined exclusion criteria and blinded analyses.
resultsPG was associated with reduced ET-1-induced hypertrophy in a concentration-dependent manner (IC
conclusionPG exhibits pharmacological cardioprotection associated with modulation of mitochondrial dynamics and attenuation of cellular stress responses. These findings support further investigation of PG as a mitochondria-engaging natural product with the potential to mitigate pathological cardiac remodeling and heart failure progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.